Convocation of the 2023 Annual General Meeting of Shareholders and Proposed Resolutions
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING
OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014).
EINDHOVEN, Pays-Bas et LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the Company), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today has convened the 2023 Annual General Meeting of Shareholders (AGM), including the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on May 8, 2023.
The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows:
- Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2022, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2022 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on March 27, 2023, and are posted on the Company’s website in the Investors section (https://ir.onwd.com) and the AFM’s website (www.afm.nl).
- Implementation of the compensation policy over the financial year 2022 (advisory non-binding voting item).
- Release from liability of the members of the Board with respect to the performance of their duties during the financial year 2022.
- Instruction to Ernst & Young Accountants LLP for the external audit of the Company's annual accounts for the financial year 2023.
- The re-appointment of Dr. Grégoire Courtine as non-executive director of the Board for a four-year term expiring at the end of the 2027 AGM.
- The appointment of Ms. Vivian Riefberg as non-executive director of the Board for a four-year term expiring at the end of the 2027 AGM.
- The delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 10% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection therewith.
- The delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 50% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection with a potential capital raise.
- The authorization to the Board to acquire ordinary shares in the capital of the Company.
The record date for all shareholders to participate at the AGM will be April 10, 2023. The convening notice, the complete agenda, and all relevant detailed information concerning the 2023 AGM, as well as all related AGM materials, are available on the Company’s website in the financial information of the Investors section (Financial Information - ONWARD Medical N.V. (onwd.com)) and made available to shareholders in compliance with legal requirements as of March 27, 2023.
To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence, and health in people with spinal cord injury, please visit ONWD.com.
About ONWARD Medical
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.
ONWARD has received eight Breakthrough Device Designations from the US FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a stimulator and wireless programmer. Positive top-line data were reported in 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the US and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed the first-in-human use of the ARC-IM neurostimulator and reported positive interim clinical outcomes for ARC-IM Therapy for improved blood pressure regulation following SCI in 2022.
ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between EPFL, the Swiss Federal Institute of Technology in Lausanne, and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com. To access our 2023 Financial Calendar, please visit IR.ONWD.com.
For Company Enquiries:
For Media Enquiries:
MC Services AG
US: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0
For Investor Enquiries:
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Transfer of Harvia’s own shares as part of remuneration of the Board30.5.2023 19:30:00 CEST | Press release
Harvia Plc, Stock Exchange Release, 30 May 2023 at 8:30 p.m. EEST Based on the decision of the General Meeting held 20 April 2023, Harvia Oyj has on 30 May 2023 transferred a total of 2,328 own shares possessed by the company to members of the Board of Directors of Harvia Oyj as part of the Board’s remuneration. After the transfer of shares as part of the board remuneration and the shares transferred at the same time under the incentive program, the company holds a total of 9,637 own shares. Based on the decision of the General Meeting of Harvia Oyj, the monthly remuneration of the Board members will be paid in company shares and in cash in such a way that approximately 40 per cent of the total monthly remuneration will be paid in company shares purchased at a price determined in public trading on Nasdaq Helsinki Ltd and approximately 60 per cent will be paid in cash. The company will pay any costs and transfer tax related to the purchase of company shares. In case the remuneration can
Vesting af warranter samt ledende medarbejderes transaktioner30.5.2023 19:18:09 CEST | pressemeddelelse
Selskabet har dags dato modtaget meddelelse om at Direktion og bestyrelse ønsker at exercise ialt 5.983.524 stk. warranter fra tildelingsåret maj 2020 (Selskabsmeddelelse 20/2020). Warrantprogrammet blev tildelt direktion og bestyrelse i maj 2020, og indehaverne af warranterne udnytter nu deres respektive programmer, og herefter udestår ingen aktieoptioner fra tildelingsåret maj 2020. Udnyttelseskursen er ved tildelingen i maj 2020 fastsat til DKK 1,53 pr. aktie af nominelt DKK 0,5, jf. selskabsmeddelelse 20/2020. Selskabet har som led i udnyttelsen af aktieoptionerne afhændet 5.983.524 stk. egne aktier til et samlet beløb på DKK 9.154.791,72, og således foretages der ingen kapitalforhøjelse i forbindelse med udnyttelsen af aktieoptionerne. Selskabets egen aktiebeholdning er efter frasalget reduceret til i alt 0 aktier. I forbindelse med gennemførelsen af ovenstående transaktioner har selskabet modtaget vedhæftede indberetninger fra direktionen og bestyrelsens respektive transaktioner.
EMGS: Notice of Annual General Meeting30.5.2023 18:30:00 CEST | Press release
Notice is hereby given of the annual general meeting of Electromagnetic Geoservices ASA ("EMGS" or the "Company"). The annual general meeting will be held at the Company's offices in Karenslyst Allé 4, 4(th) floor, 0278 Oslo, Norway on 21 June 2023 at 12:00 local time. The calling notice is attached to this stock exchange notification, and will, together with all appendixes and the Company's annual report for 2022 be published on the Company's webpage www.emgs.com. Contact Anders Eimstad, Chief Financial Officer, +47 948 25 836 About EMGS EMGS, the marine EM market leader, uses its proprietary electromagnetic (EM) technology to support oil and gas companies in their search for offshore hydrocarbons. EMGS supports each stage in the workflow, from survey design and data acquisition to processing and interpretation. The Company's services enable the integration of EM data with seismic and other geophysical and geological information to give explorationists a clearer and more complete unde
Monument Heads Toward Commercial Production at Selinsing Gold Mine30.5.2023 18:21:56 CEST | Press release
VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) ("Monument" or the "Company") is pleased to update the progress at the Selinsing Sulphide Project. The ramp-up of the flotation plant has made great headway, with the mill feed rate of 113 dry tonnes per hour achieved, being 95% of the design capacity of 119 dry tonnes per hour. The plant construction and mine development consumed a total of $18 million, in line with the budget. President and CEO Cathy Zhai commented, “We are very pleased with the flotation plant ramp-up progress as we head towards full commercial production. We have commenced sulphide production in January 2023 and continue testing and adjusting to improve plant performance through the action plan. Despite several incidental plant shutdowns during March to May, the plant is expected to reach its near or full production level by June 2023, within the planned ramp up period of three to six months. To date, th
Results of additional issuance - RIKB 28 111530.5.2023 17:31:00 CEST | Press release
As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 26. May, at the price of accepted bids. SeriesRIKB 28 1115ISINIS0000028249Additional issuance (nominal)29,000,000Settlement date05/31/2023Total outstanding (nominal)103,350,801,519